| Company Name: |
Xi'an Manareco New Materials Co., Ltd.
|
| Tel: |
029-02968669089-8816 |
| Email: |
market@xarlm.com |
| Products Intro: |
Product Name:2-(3,4-DiMethoxy-phenyl)-5-(3-Methoxy-propyl)-benzofuran
CAS:1018946-38-7
Purity:GC>99% Package:>50Kg
|
|
| | DWK-1339 Basic information |
| Product Name: | DWK-1339 | | Synonyms: | DWK-1339;2-(3,4-DiMethoxy-phenyl)-5-(3-Methoxy-propyl)-benzofuran;Benzofuran, 2-(3,4-diMethoxyphenyl)-5-(3-Methoxypropyl)-;2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)-1-benzofuran;DWK-1339;DWK 1339;DWK1339;SNU-0039;SNU-0039 (DWK-133);MDR1339,DWK1339,inhibit,β-amyloid peptide,Inhibitor,MDR 1339,Abeta,Amyloid-β,MDR-1339,DWK 1339 | | CAS: | 1018946-38-7 | | MF: | C20H22O4 | | MW: | 326.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1018946-38-7.mol |  |
| | DWK-1339 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 30mg/mL; DMSO: 30mg/mL; Ethanol: 2mg/mL | | form | A crystalline solid | | color | White to off-white |
| | DWK-1339 Usage And Synthesis |
| Description | DWK-1339 is an inhibitor of amyloid-β (Aβ) aggregation. It inhibits aggregation of monomeric Aβ (1-42) (Aβ42) and induces disaggregation of Aβ42 fibrils in vitro when used at concentrations ranging from 3.1 to 50 μM. DWK-1339 (10 μM) reduces Aβ42-induced toxicity in HT-22 cells. In vivo, DWK-1339 (10 mg/kg) increases step-through latency in a passive avoidance test and increases spontaneous alteration in the Y-maze compared with vehicle control mice in a mouse model of Aβ42-induced acute Alzheimer''s disease. It also decreases brain levels of Aβ42 and increases spontaneous alteration in the Y-maze in the APP/PS1 transgenic mouse model of Alzheimer''s disease. | | Uses | DWK-1339, is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer''s disease. |
| | DWK-1339 Preparation Products And Raw materials |
|